Dr. Spigel Discusses MPDL3280A Development in Lung Cancer

Video

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses current trials involving MPDL3280A in lung cancer.

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses current trials investigating the anti-PD-L1 antibody MPDL3280A in lung cancer.

There are a number of ongoing trials investigating MPDL3280A in lung cancer, following the presentation of promising data from a phase I trial investigating the drug in lung cancer at last year’s ASCO. One trial is looking at MPDL3280A versus docetaxel in unselected patients. However, there are also single cohort studies where patients receive the drug in PD-L1 positive tumors, Spigel says.

Two of these studies are designed to enroll patients in the first-line setting, second-line and beyond, and in patients with CNS metastasis. Spigel is hopeful that as the single-arm studies mature and the randomized registration trials mature, new options will be available in lung cancer.

<<<

View more from the 2014 ASCO Annual Meeting

Related Videos
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania